Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes. Issue 6 (3rd June 2017)

• Record Type: Journal Article
• Authors: Østergaard, Lauge; Frandsen, Christian Seerup; Dejgaard, Thomas Fremming; Madsbad, Sten
• Is Part Of: Expert review of clinical pharmacology. Volume 10:Issue 6(2017)
• Page Start: 621
• Page End: 632
• Publication Date: 2017-06-03
• Subjects: Degludec -- glargine -- GLP-1 receptor agonist -- liraglutide -- DUAL -- type 2 diabetes; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2017.1313109
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction : A fixed combination of basal insulin degludec and glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide (IDegLira; 50 units degludec/1.8 mg liraglutide) has been developed as a once daily injection for the treatment of type 2 diabetes (T2D). In the phase 3a trial programme 'Dual action of liraglutide and insulin degludec in type 2 diabetes' (DUAL™), five trials of 26 weeks duration and one trial of 32 weeks duration have evaluated the efficacy and safety of IDegLira compared with administration of insulin degludec, insulin glargine, liraglutide alone or placebo. Areas covered : Combination therapy with IDegLira reduces HbA1c more than monotherapy with a GLP-1RA (liraglutide) or insulin (degludec or glargine). Combination therapy leads also to weight loss, or a stable body weight, with no increase in hypoglycaemia. Rates of adverse events did not differ between treatment groups; however, gastrointestinal side effects were fewer with IDegLira compared with liraglutide treatment alone. A limitation of the DUAL™ development programme is that patients receiving basal insulin doses in excess of 50 units were excluded from the studies. Expert commentary : In conclusion, IDegLira combines the clinical advantages of basal insulin and GLP-1RA treatment, and is a treatment strategy that could improve the management of patients with T2D.